1. BUYtheWeak
2. nlanas2sk051p
3. johnhoar
4. MamisTrist
5. orangepa53
1.johnhoar 02/08/2018
BMO Capital reiterates
2.johnhoar 03/10/2018
Praluent® (alirocumab) Injection Significantly Reduced Risk of Cardiovascular Events in High-Risk Patients, and was Associated with Lower Death Rate
3.MamisTrist 09/12/2017
Time to buy?
4.johnhoar 04/03/2018
EMA to Review Cemiplimab as a Potential Treatment for Advanced Cutaneous Squamous Cell Carcinoma
5.BUYtheWeak 09/12/2017
@MamisTrist Yup, looking like it if you haven't already
6.johnhoar 01/30/2018
Great news - Company granted orphan drug designation by the FDA for its compound for the treatment of follicular lymphoma
7.BUYtheWeak 04/30/2018
FDA to Conduct Priority Review of Cemiplimab as a Potential Treatment for Advanced Cutaneous Squamous Cell Carcinoma
8.nlanas2sk051p 02/08/2018
Seeing EPS beats reported by $0.63 and by $0.70. Beats on revenues.
9.MamisTrist 03/02/2018
FDA to Review DUPIXENT® (dupilumab) as Potential Treatment for Moderate-to-Severe Asthma
10.BUYtheWeak 01/24/2018
More good news
NEW since the last time you visited this board.
Currently a TOP 10 POST for this board.
Currently a TOP 5 RESEARCHER for this board.
Specific post has replies to it.
A Researcher you are currently FOLLOWING
Other Researchers rate this post HIGH
Other Researchers rate this post LOW